Dr Albert Bouria the CEO and Chairman of Pfizer announced earlier today that the vaccine which Pfizer has been developing with BioNTech has achieved a better then 90% success at protecting individuals from Covid-19.

The positive, but incomplete study brings the world one giant step closer to a vaccine solution to the global Covid plague.

Pfizer is extremely bullish on its predictions that it will ask regulators for early approval to sell shots of the vaccine by the end of November. This optimism is as a result of an early analysis by an external independent committee which has reported extremely positive and promising results of the vaccine.

However, a few words of caution might be appropriate before we get too carried away. The FDA has indicated that that approval might take up to two months because it requires assessing and monitoring the trial subjects fro side effects. Secondly while the mRNA-based vaccine has proved to be efficacious, the vaccines length of immunity is still unknown and may not be known for many months to come.

As for the vaccine itself, Pfizer and BioNTech developed a new and unproven technology known as mRNA. The vaccine shots deliver messenger RNA (known as molecular couriers) to cells with genetic instructions. These prompt the cells to make synthetic versions of the spike protein and this triggers the immune system to defend against the virus.

The announced today is a real game changer in the world of vaccine development. The speed, the professionalism, the global cooperation to develop a cure has been breathtaking. The fight to defeat the virus has in a sense been won, but the war against the global pandemic is far from over.

Manufacturing billions of doses of a vaccine and vaccinating millions of people in a meaningful way will take global planning, high tech logistics and extreme caution on a global scale never attempted before.

This is especially true of the mRNA vaccine which requires two doses over 28 days. Moreover distribution of the Pfizer vaccine will be a nightmare because the vaccine cannot be stored in a typical doctor’s office refrigerator. The vaccine will require custom-built low temperature freezers that can store the medicine at minus 94 degrees.

One thing is for sure; today’s news is a clear indication that we have found a path that will eventually lead us back to near normalisation